达维塔将24财年每股收益预期提高至9.25-10.05美元,超过第二季度的估计,每股收益为2.59美元,收入为319亿美元. DaVita raises FY24 EPS guidance to $9.25-10.05, outperforms Q2 estimates with $2.59 EPS and $3.19B revenue.

达维塔 (NYSE:DVA) 更新了其24财年利预测,每股收益为9.25-10.05美元,高于之前的共识估计9.63美元. DaVita (NYSE:DVA) updated its FY24 earnings guidance to $9.25-10.05 EPS, up from the previous consensus estimate of $9.63. Davita报告,Q2收入为2.59 EPS和3.19B收入,超过分析家的估计。 DaVita reported Q2 earnings of $2.59 EPS and $3.19B revenue, outperforming analysts' estimates. 该公司的股票在交易时间达到138.18美元,市场上限为12.12B美元。 The company's stock reached $138.18 during trading hours, with a market cap of $12.12B. Davita经营肾脏透析中心,并在门诊透析中心、住院病人和家庭的透析服务中提供相关的实验室服务。 DaVita operates kidney dialysis centers and provides related lab services in outpatient dialysis centers, inpatient, and home-based hemodialysis services. 美国银行将DVA的价格目标从139美元提高到145美元, Bank of America raised its price target for DVA from $139 to $145, while maintaining an "underperform" rating.